Through purpose-driven science, empowering medicines, and transformative advocacy we seek to improve the lives of millions.
Myovant is developing innovative medicines that hold promise to improve people’s lives.
10 May 2022
Myovant Sciences Announces Corporate Updates and Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2022
9 May 2022
Myovant Sciences and Accord Healthcare, Ltd. Enter into Exclusive License Agreement to Commercialize ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in Europe
6 May 2022
Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis
29 Apr 2022
Myovant Sciences Announces European Commission Approval for ORGOVYX® (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer
You are leaving www.myovant.com, a website provided by Myovant Sciences GmbH.
This link will take you to a different site.